港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,656.921

-15.995-0.96%

漲家數：2

跌家數：6

平家數：- -

市盈率：- -

高：1,689.707

開：1,673.364

低：1,646.606

收：1,672.916

資料載入中...

藥明康德(02359)公佈第一季度業績歸母淨利約36.72億元同比增長89.06%

智通财经网

《藍籌》藥明康德(02359.HK)首季純利升89.1%至36.72億人幣

阿斯达克财经

泰格醫藥：2025年第一季度淨利潤1.65億元，同比下降29.61%。

《業績》泰格醫藥(03347.HK)首季純利1.65億元人民幣按年跌29.6%

阿斯达克财经

藥明康德(02359)4月28日斥資2000.79萬元回購A股34.78萬股

Sands Frank Melville Jr.減持泰格醫藥(03347)約37.05萬股每股作價約25.53港元

智通财经网

方達控股盤中異動股價大跌5.08%報1.120港元

金斯瑞生物科技(01548)出現大手買入53.4萬股，成交價$11.26，涉資601.284萬

阿斯达克财经

昂利康(002940.SZ)：創新藥注射用ALK-N001獲得藥物臨牀試驗批准通知書

【首藥控股：擬不超7.87億元建設新藥研發與產業化基地項目】首藥控股4月27日晚間公告，公司擬以自有及自籌資金不超過7.87億元，在亦莊新城國際醫藥創新公園自主建設新的“首藥控股新藥研發與產業化基地”項目，並與北京經濟技術開發區管委會簽署《經濟發展合作協議》。該合作協議生效後，公司將按照招拍掛供應程序取得項目宗地，建設包括研發中心、質控中心、臨牀試驗中心、銷售中心及生產基地在內的公司新總部，建設期3年。

康龍化成一季報超預期！

财经自媒体

康龍化成(03759)提名萬璇為第三屆董事會非執行董事候選人

康龍化成擬委任萬璇為非執行董事

康龍化成(03759.HK)一季度淨利增32.54%至3.06億元新簽訂單金額同比增長超10%

石藥集團(01093.HK)新藥SYH2068注射液獲準開展臨牀試驗

阿斯达克财经

長春金賽藥業有限責任公司藥品申請臨牀試驗默示許可獲受理

江蘇威凱爾醫藥科技股份有限公司藥品申請臨牀試驗默示許可獲受理

山東京衞製藥有限公司藥品申請臨牀試驗默示許可獲受理

安徽中盛溯源生物科技有限公司藥品申請臨牀試驗默示許可獲受理

和徑醫藥科技（上海）有限公司藥品申請臨牀試驗默示許可獲受理

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1656.921,"timestamp":1746000495720,"preClose":1672.9159,"halted":0,"volume":46989588,"delay":0,"changeRate":-0.009561,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-15.994873,"latestTime":"04-30 16:00:00","open":1673.3644,"high":1689.7068,"low":1646.6055,"amount":1196093850,"amplitude":0.025764,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"pbRate":1.989191,"peRate":9.524219,"turnoverRate":0.003721,"increases":2,"decrements":6,"flats":0,"marketCap":350848075776,"floatMarketCap":154609044736},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1689.7068,"amplitude":0.025764,"preClose":1672.9159,"low":1646.6055,"pbRate":"1.989191","latestPrice":1656.921,"volume":46989588,"delay":0,"open":1673.3644,"prevYearClose":1395.7731,"prevWeekClose":1649.561,"prevMonthClose":1656.921,"prevQuarterClose":1941.338,"fiveDayClose":1645.051,"twentyDayClose":1942.366,"sixtyDayClose":1438.36,"secType":"PLATE","market":"HK","turnoverRate":0.003721,"peRate":9.524219,"marketCap":350848075776,"floatMarketCap":154609044736,"timestamp":1746000495720,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":2,"down":6,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530205424","title":"藥明康德(02359)公佈第一季度業績 歸母淨利約36.72億元 同比增長89.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530205424","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530205424?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 17:20","pubTimestamp":1745832000,"startTime":"0","endTime":"0","summary":"药明康德公布2025年第一季度业绩，营业收入约96.55亿元，同比增长20.96%;归属于上市公司股东的净利润约36.72亿元，同比增长89.06%;基本每股收益1.29元。截至2025年3月末，公司持续经营业务在手订单人民币523.3亿元，同比增长47.1%。报告期内来自美国客户收入人民币63.8亿元，同比增长28.4%;来自欧洲客户收入人民币13.0亿元，同比增长26.2%;来自中国客户收入人民币15.3亿元，同比下降1.3%;来自其他地区客户收入人民币4.5亿元，同比增长3.0%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-28/doc-ineutiyu1909671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2045819591.USD","BK1576","LU2495084118.USD","02359","LU0708995583.HKD","603259","BK1141","LU1997245094.SGD","LU2125910500.SGD","LU0052750758.USD","LU1997245177.USD","BK1583","LU0320764599.SGD","LU0456842615.SGD","LU1046422090.SGD","LU1997244956.HKD","BK0216","LU2242644610.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"2530243254","title":"《藍籌》藥明康德(02359.HK)首季純利升89.1%至36.72億人幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2530243254","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530243254?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 17:19","pubTimestamp":1745831940,"startTime":"0","endTime":"0","summary":"药明康德(02359.HK) 公布截至今年3月底止首季业绩，以中国企业会计准则计，营业额96.55亿元人民币(下同)，按年升21%。纯利36.72亿元，按年升89.1%；基本每股盈利1.29元。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-28 16:25。)过往派息公布日期派息事项派息内容2025/03/17末期业绩特别股息：人民币 0.35002025/03/17末期业绩股息：人民币 0.98172024/10/28第三季业绩无派息2024/07/29中期业绩无派息AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220419153917927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220419153917927_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436438/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1997244956.HKD","02359","LU2045819591.USD","BK1576","LU1997245177.USD","LU0708995583.HKD","LU0052750758.USD","LU0320764599.SGD","603259","BK0216","LU1046422090.SGD","LU2125910500.SGD","LU2495084118.USD","LU0456842615.SGD","LU2242644610.SGD","BK1583","LU1997245094.SGD","LU2488822045.USD","BK1141"],"gpt_icon":0},{"id":"2530219964","title":"泰格醫藥：2025年第一季度淨利潤1.65億元，同比下降29.61%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530219964","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530219964?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 17:16","pubTimestamp":1745831789,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1146622755.USD","300347","BK0077","03347","BK1141","BK0174","BK0028","BK0216","BK1583","BK1576","LU1820825898.SGD"],"gpt_icon":0},{"id":"2530424535","title":"《業績》泰格醫藥(03347.HK)首季純利1.65億元人民幣  按年跌29.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530424535","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530424535?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 17:03","pubTimestamp":1745830980,"startTime":"0","endTime":"0","summary":"泰格医药(03347.HK) 公布截至今年3月底止首季业绩，营业额15.64亿元人民币(下同)，按年跌5.8%。纯利1.65亿元，按年跌29.6%；每股盈利0.19元。(ha/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-28 16:25。)过往派息公布日期派息事项派息内容2025/03/27末期业绩股息：人民币 0.30002024/10/29第三季业绩无派息2024/08/28中期业绩无派息2024/04/25第一季业绩无派息AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210301160530229_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210301160530229_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436431/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0216","BK1576","BK0028","BK0174","LU1820825898.SGD","BK1141","BK1583","300347","LU1146622755.USD","03347","BK0077"],"gpt_icon":0},{"id":"2530942361","title":"藥明康德(02359)4月28日斥資2000.79萬元回購A股34.78萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2530942361","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530942361?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 16:28","pubTimestamp":1745828909,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，于2025年4月28日斥资2000.79万元回购A股股份34.78万股，每股回购价格为57.12-58.53元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399300","LU2488822045.USD","LU0320764599.SGD","LU1046422090.SGD","159982","LU1997245177.USD","02359","LU2242644610.SGD","LU2125910500.SGD","LU0708995583.HKD","LU1997244956.HKD","BK1583","LU2495084118.USD","BK0216","BK1576","603259","LU0456842615.SGD","LU1997245094.SGD","LU0052750758.USD","BK1141","LU2045819591.USD"],"gpt_icon":0},{"id":"2530303447","title":"Sands Frank Melville Jr.減持泰格醫藥(03347)約37.05萬股 每股作價約25.53港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530303447","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530303447?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 15:20","pubTimestamp":1745824815,"startTime":"0","endTime":"0","summary":"减持后最新持股数目约为964.55万股，最新持股比例为7.83%。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20250428/20250428152036_71730.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250428/20250428152036_71730.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300347","BK1576","LU1146622755.USD","BK1141","BK1583","LU1820825898.SGD","BK0077","03347","BK0174","BK0028","BK0216"],"gpt_icon":0},{"id":"2530442422","title":"方達控股盤中異動 股價大跌5.08%報1.120港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530442422","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530442422?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 15:16","pubTimestamp":1745824614,"startTime":"0","endTime":"0","summary":"2025年04月28日下午盘15时16分，方达控股股票出现异动，股价大幅下挫5.08%。截至发稿，该股报1.120港元/股，成交量6.5875万股，换手率0.00%，振幅5.08%。资金方面，该股资金流入4.208万港元，流出1.148万港元。方达控股股票所在的生物技术行业中，整体跌幅为0.34%。其相关个股中，君实生物、中国抗体-B、创胜集团-B涨幅较大，振幅较大的相关个股有云康集团、君实生物、中国抗体-B，振幅分别为16.05%、13.75%、13.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428151654a46a0d70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428151654a46a0d70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1583","01521","BK1141"],"gpt_icon":0},{"id":"2530958490","title":"金斯瑞生物科技(01548)出現大手買入53.4萬股，成交價$11.26，涉資601.284萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2530958490","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530958490?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 10:50","pubTimestamp":1745808600,"startTime":"0","endTime":"0","summary":"[大手成交]金斯瑞生物科技(01548)在上午10:50出现大手买入，成交量为53.4万，成交价为港币$11.26，涉资601.284万。至目前为止，股价升1.627%，今日最高价为$11.54，而最低价为$10.8，总成交量为681.237万股，总成交金额港币$7.605千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2504285805/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000320223.HKD","HK0000306685.HKD","BK1141","01548","HK0000306701.USD","BK1583","BK1576","HK0000320264.USD"],"gpt_icon":0},{"id":"2530453276","title":"昂利康(002940.SZ)：創新藥注射用ALK-N001獲得藥物臨牀試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2530453276","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530453276?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 21:37","pubTimestamp":1745761057,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨昂利康公布，近日，浙江昂利康制药股份有限公司收到国家药品监督管理局签发的注射用ALK-N0011《药物临床试验批准通知书》。临床前研究结果显示，注射用ALK-N001在HT1080及CT26模型中，ALK-N001均能剂量依赖性抑制肿瘤生长。综合临床前研究结果，ALK-N001显示了良好的药效和安全性，是一款极具创新性与开发潜力的小分子偶联抗肿瘤药物，有望为晚期实体瘤患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27213749931252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4008","BK1574","BK4588","BK1576","BK1141","BK4500","BK0239","BK1583","ALK","06978","03347","159992","BK1161","002940","BK4585"],"gpt_icon":0},{"id":"2530453653","title":"【首藥控股：擬不超7.87億元建設新藥研發與產業化基地項目】首藥控股4月27日晚間公告，公司擬以自有及自籌資金不超過7.87億元，在亦莊新城國際醫藥創新公園自主建設新的“首藥控股新藥研發與產業化基地”項目，並與北京經濟技術開發區管委會簽署《經濟發展合作協議》。該合作協議生效後，公司將按照招拍掛供應程序取得項目宗地，建設包括研發中心、質控中心、臨牀試驗中心、銷售中心及生產基地在內的公司新總部，建設期3年。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530453653","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530453653?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 21:24","pubTimestamp":1745760272,"startTime":"0","endTime":"0","summary":"首药控股4月27日晚间公告，公司拟以自有及自筹资金不超过7.87亿元，在亦庄新城国际医药创新公园自主建设新的“首药控股新药研发与产业化基地”项目，并与北京经济技术开发区管委会签署《经济发展合作协议》。该合作协议生效后，公司将按照招拍挂供应程序取得项目宗地，建设包括研发中心、质控中心、临床试验中心、销售中心及生产基地在内的公司新总部，建设期3年。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/27212449931207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","09939","BK1576","BK1141","BK1161","159938","BK1583","BK1515","03347","BK1574","688197"],"gpt_icon":0},{"id":"2530845806","title":"康龍化成一季報超預期！","url":"https://stock-news.laohu8.com/highlight/detail?id=2530845806","media":"财经自媒体","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530845806?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 20:54","pubTimestamp":1745758440,"startTime":"0","endTime":"0","summary":"今天，康龙化成发了一季报，不错，营收+16%、净利润+32.5%、扣非净利润+56%：分业务看，实验室服务营收+15.7%、小分子CDMO+19%、临床研究服务+14%、新业务+7.9%：大分子和细胞与基因治疗算是康龙化成新开辟的业务，收入规模不大，只有9869万，按道理，新业务增速应该更快，但康龙的增长只有8%，毛利率还是负的38.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-04-27/doc-ineurmin9709234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","BK1141","03759","300759","BK1576"],"gpt_icon":0},{"id":"2530316334","title":"康龍化成(03759)提名萬璇為第三屆董事會非執行董事候選人","url":"https://stock-news.laohu8.com/highlight/detail?id=2530316334","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530316334?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:56","pubTimestamp":1745751378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康龙化成(03759)发布公告，胡柏风已自愿辞任公司非执行董事及董事会战略委员会委员。胡柏风辞任后，彼自愿同意继续履行非执行董事及战略委员会委员的职责，直至公司股东于即将举行的公司2024年股东周年大会上选举产生新非执行董事为止。2025年4月25日，董事会审议通过了关于提名万璇为第三届董事会非执行董事候选人的议案。委任万璇为非执行董事须待股东于2024年股东周年大会上选举通过后，方可作实。待于2024年股东周年大会上委任获作实后，万璇亦将担任战略委员会委员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","03759","BK1576","300759","BK1141"],"gpt_icon":0},{"id":"2530395984","title":"康龍化成擬委任萬璇為非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2530395984","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530395984?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:26","pubTimestamp":1745749560,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨康龙化成(03759.HK)宣布，胡柏风已自愿辞任公司非执行董事及董事会战略委员会委员。胡先生辞任后，彼自愿同意继续履行非执行董事及战略委员会委员的职责，直至公司股东于即将举行的公司2024年股东周年大会上选举产生新非执行董事为止。2025年4月25日，董事会审议通过了关于提名万璇为第三届董事会非执行董事候选人的议案。委任万璇为非执行董事须待股东于2024年股东周年大会上选举通过后，方可作实。追加内容本文作者可以追加内容哦 !","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427183103a46914f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427183103a46914f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","BK1576","BK1141"],"gpt_icon":0},{"id":"2530000436","title":"康龍化成(03759.HK)一季度淨利增32.54%至3.06億元  新簽訂單金額同比增長超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530000436","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530000436?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:14","pubTimestamp":1745748883,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨康龙化成发布2025年第一季度报告，报告期内，公司实现营业收入人民币 30.99亿元，同比增长16.03%；归属于上市公司股东的净利润人民币3.06亿元，同比增长32.54%；归属于上市公司股东的扣除非经常性损益的净利润人民币 2.92亿元，同比增长56.08%，基本每股收益人民币0.1736元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27181449929806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","03759","BK0216","300759","BK1576"],"gpt_icon":0},{"id":"2530330844","title":"石藥集團(01093.HK)新藥SYH2068注射液獲準開展臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530330844","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530330844?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 17:47","pubTimestamp":1745747220,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公布，集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA)获中国国家药品监督管理局批准，可以在内地开展临床试验。该产品适用于治疗高脂蛋白血症，通过优化序列和化学修饰的策略来实现更持久的基因沉默效果，具有预防动脉粥样硬化性心血管疾病的潜力。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436132/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1583","LU1226287792.SGD","LU1152091168.USD","LU0880133367.SGD","01093","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0501845795.SGD","BK1191","SG9999004220.SGD","LU1993786604.SGD","BK1515","LU1226288170.HKD","LU1226287875.USD","LU1807302812.USD","BK1576","BK1521","LU0140636845.USD","03347","LU1226288253.USD","LU1960683339.HKD","LU0326950275.SGD","IE0008369823.USD","LU0067412154.USD","LU1008478684.HKD","LU1226287529.USD","IE00BZ08YR35.GBP","IE0008368742.USD","LU0072913022.USD","BK1141","IE00B031HY20.USD","LU1951186391.HKD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2530848483","title":"長春金賽藥業有限責任公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530848483","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530848483?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，长春金赛药业有限责任公司联合申请药品“伏欣奇拜单抗注射液”，获得临床试验默示许可，受理号CXSL2500163。通过天眼查大数据分析，长春金赛药业有限责任公司共对外投资了17家企业，参与招投标项目743次，知识产权方面有商标信息507条，专利信息105条，此外企业还拥有行政许可85个。主要股东信息显示，长春金赛药业有限责任公司由长春高新技术产业（集团）股份有限公司持股99.5%、金磊持股0.5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","03347","BK1583","BK1576"],"gpt_icon":0},{"id":"2530835874","title":"江蘇威凱爾醫藥科技股份有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835874","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835874?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，江苏威凯尔医药科技股份有限公司联合申请药品“VC005片”，获得临床试验默示许可，受理号CXHL2500200。江苏威凯尔医药科技股份有限公司，成立于2010年，位于南京市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，江苏威凯尔医药科技股份有限公司共对外投资了3家企业，参与招投标项目19次，知识产权方面有商标信息12条，专利信息47条，此外企业还拥有行政许可74个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","03347","BK1576","BK1161","09939","159938","BK1583","BK1515","BK1574"],"gpt_icon":0},{"id":"2530835584","title":"山東京衞製藥有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835584","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835584?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，山东京卫制药有限公司联合申请药品“米诺地尔泡沫剂（男用）”，获得临床试验默示许可，受理号CYHL2500041。山东京卫制药有限公司，成立于1993年，位于泰安市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，山东京卫制药有限公司共对外投资了2家企业，参与招投标项目1749次，知识产权方面有商标信息146条，专利信息129条，此外企业还拥有行政许可182个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","01477","BK1191","BK1574","BK1583","BK1141","BK1576"],"gpt_icon":0},{"id":"2530835324","title":"安徽中盛溯源生物科技有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835324","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835324?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，安徽中盛溯源生物科技有限公司、中盛溯源（广州）生物科技有限公司联合申请药品“NCR201注射液”，获得临床试验默示许可，受理号CXSL2500126。安徽中盛溯源生物科技有限公司，成立于2016年，位于合肥市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，安徽中盛溯源生物科技有限公司共对外投资了5家企业，参与招投标项目11次，知识产权方面有商标信息60条，专利信息30条，此外企业还拥有行政许可11个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159837","BK1576","03347","BK1583","BK1141"],"gpt_icon":0},{"id":"2530483315","title":"和徑醫藥科技（上海）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530483315","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530483315?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，和径医药科技（上海）有限公司联合申请药品“HJ-002-03片”，获得临床试验默示许可，受理号CXHB2500069。和径医药科技（上海）有限公司，成立于2017年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，和径医药科技（上海）有限公司专利信息14条，此外企业还拥有行政许可3个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1161","BK1515","BK1574","09939","BK1583","BK1576","159938","03347"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}